“EUR60 million have so far been invested, not only in the generic medicine section, which we hope to start producing soon, but mainly in the cancer drug section which will be completed this year and is the most modern production line in Romania and in Southeastern Europe,” Tudor Iures, general manager of Polipharma Industries, said Monday at the ZF Pharma & Health Summit ’14.

Iures also said that EUR20 million are covered from European Union funds and the rest comes from the plant’s owners, the Vonica Family. He added that Polipharma Industries’ turnover is expected to reach RON15 million in 2014 and RON40 million in 2015.

Polipharma currently manufactures solid products, of which 50 are dietary supplements and ten are over-the-counter (OTC) drugs.

End-August this year, Romanian lawyer Remus Borza was appointed president of the group of firms Polisano, which operates mainly in the healthcare industry, two months after the group’s founder, doctor Ilie Vonica, had killed himself.

Early June 2014, the owner of Polisano group, Ilie Vonica, committed suicide two weeks after his wife had been arrested, alongside other people, on charges of illegally receiving money from the national health insurance house over bogus cancer-drug prescriptions.

Vonica, a doctor who specialized as a gynecologist, began his healthcare business with his wife in 1993 after the anti-communist revolution, when private health care took off.

The Polisano group, founded in 1993, also includes medical centers, in vitro fertilization clinics, a private hospital in Sibiu, the Reteta pharmacy chain, drugmaker Polipharma Sibiu, a Toyota dealership, a Citröen auto repair shop, a travel agency, sports and leisure projects, constructions and real estate.